Kornimate/medical-research-clean huggingface dataset:
retrospective study of pediatric patients with covid-19 in alsace in 2020-2021

Conditions: COVID-19 Pandemic

Summary: covid-19 is an illness that appeared in china between the end of december 2019 and the beginning of 2020 after several cases of pneumonia of undetermined etiology were reported in the hubei province in central china. these are caused by a previously unknown coronavirus, initially named 2019-ncov then sars-cov-2, which was identified on january 7, 2020 in the bronchoalveolar lavage (bal) of patients hospitalized in china. as for the first european cases, they were diagnosed in france on january 24, 2020. a chinese study published in april 2020 (4) concerning adult patients showed that 14% of these cases could be defined as severe and that 5% of cases could be defined as critical. another chinese study showed that all children, regardless of age, could be infected and that asymptomatic, mild and moderate cases accounted for more than 90% of cases. in france, the covid-19 epidemic hit alsace hard from march 2020, mainly due to the cluster formed by the evangelical assembly of the christian open door church taking place from february 17 to 21 in mulhouse in the haut-rhin. thus, it is interesting to study pediatric patients hospitalized for covid-19 in alsace during 2020 in order to discover the clinical characteristics of these patients.

the main objective of this study is to retrospectively describe the clinical, biological and radiological characteristics of pediatric patients hospitalized for covid-19 in alsace in 2020-2021, both in conventional service and in continuing care or intensive care.

Eligibility criteria:
inclusion criteria: * subject aged from 1 month to 18 years * hospitalized for covid-19 in conventional service, continuing care or intensive care for covid-19 or in whom sars-cov-2 infection was strongly suspected during the allat period from january 1, 2020 to december 31, 2021 * subject who has not expressed, after information, his opposition to the reuse of his data for the purposes of this research * parental authority having not expressed, after information, their opposition to the reuse of their data for the purposes of this research. exclusion criteria: * subject or their parental authority having expressed their opposition to participating in the study

Keywords: covid-19 pandemic sars-cov-2 covid-19 virus disease pediatric patients
effects of system suspended robotic lokomat gait in patients with incomplete spinal cord injury

Conditions: Spinal Cord Injury

Summary: patients with incomplete spinal cord injury

the objective of this project is to verify the effects of suspended robotic gait training (lokomat) in recovery of functional capacity of the lower limbs patients with incomplete spinal cord injury.

Eligibility criteria:
inclusion criteria: * clinical and radiological diagnosis of incomplete spinal cord injury of traumatic origin * injury time from 1 to 36 months * stability verified in clinical medical evaluation * asia c or d * absence of severe psychiatric amendment requiring psychiatric evaluations * present functional recovery of the upper limb compatible with stages iii and iv of brunnstrom * patients cannot use a cardiac pacemaker ; have unstable angina or other decompensated heart disease; have chronic obstructive pulmonary disease; dysreflexia without having autonomic control; have some fracture of the bones of the lower limbs; tracheostomy; presenting deformity and stiffness of the hip joint, knee (20 ° or more of flexion ) and ankle ( 10 or more plantar flexion ) and pressure ulcers. * absence of illicit drug use * grant writing the informed consent to participate in the study exclusion criteria: * lack of resistance * disabling fatigue * worsening of spasticity which prevents the movement * body weight in excess of 150kg * risk of osteoporosis with pathological fracture * asymmetry in the lower limbs greater than 2 cm * skin lesions and / or pressure ulcers in areas where the orthosis lokomat pressuring

Keywords: rehabilitation walking robotics neuronal plasticity
consumer study for the evaluation of the usability and efficacy of one medical device in venous return

Conditions: Venous Disease; Quality of Life; Symptoms and Signs

Summary: the primary goal of this study is to assess in vivo the efficacy of the insoles in improving venous return in subjects affected by this problem after 14 days of medical device use, by self-assessment, filling-in questions regarding quality of life, in comparison to the baseline. the secondary goals of this study are (1) to assess in vivo the perception of subjects about the rapid relief felt after 7 days of using the same medical device, by self-assessment, filling-in three subjective evaluation questions, and (2) to assess in vivo the usability of the subjects regarding the same medical device after 14 days of its use, by self-assessment, filling-in subjective evaluation questions.


Eligibility criteria:
inclusion criteria: * gender: female/male; * age: with 18 years old and older; * having signed an informed consent form (icf); * willingness, ability and likeliness to comply with all the study procedures and restrictions; * ability to give informed consent; * available during the entire study period; * understanding portuguese language: portuguese-speaking subjects capable of reading the documents; * affected by a symptomatic venous return problem; exclusion criteria: * known allergy or known history of hypersensitivity to the components of the investigational device and related compounds; * currently participating in another clinical study that may interfere with the study; * diagnosed skin diseases and/or cutaneous alterations on the test region (feet) that may impair the study (for example tattoos, marks, burns, scars, etc.); * diagnosed diseases that may impair the study (including but not limited to: diabetes, arteritis, phlebitis, etc); * under pharmacological treatments on the 30 days previous to the beginning of the study and during the entire period of the study that may impair it (including but not limited to: inflammatory drugs, any drug that might cover the signs and symptoms, drugs with arterial or venous indications, etc.); * having applied any type of topical product (pharmaceutical, cosmetic or other) with similar effect of the medical device under study, on the test region (feet) during the study, besides the investigational device; * having a stage of cvd c3 on the ceap classification; * having had a traumatic or neurological history in the last 6 months; * wearing an orthopaedic insole made by a health professional; * having a significant and disabling lower limb pain; * having a significant and disabling back pain; * having a contraindication to wearing insoles; * pregnancy or intention to conceive during the study; * breast-feeding

Keywords: chronic venous disease, insoles, quality of life, symptoms, relief,
connecting the lab to everyday life: the relevance of executive dysfunction to participation and quality of life in parkinson's disease (pd) without dementia

Conditions: Parkinson's Disease

Summary: the overall purpose of this research is to learn how parkinson's disease affects thinking and memory in everyday life. participation will involve thinking tests, questionnaires and interviews about thinking and activities in everyday life.

the overall purpose of this research is to learn how parkinson's disease affects thinking and memory in everyday life. participation will involve thinking tests, questionnaires and interviews about thinking and activities in everyday life.

Eligibility criteria:
inclusion criteria pd participants: * wusm movement disorders clinic patients * males or females between 40 and 70 * meet criteria for idiopathic typical pd * classified at hoehn \& yahr12 stage i, ii, or iii * are currently treated with levodopa/carbidopa inclusion criteria control: * the groups will be matched for age, education and gender * no parkinson disease exclusion criteria pd participants and control: * suspected dementia * treatment with certain dopaminergic, anticholinergic or benzodiazepine medications * other neurological problems * brain surgery * history or current psychotic disorder * any condition which would interfere with testing * control only: a biological family history of pd and being a caregiver or spouse of someone who has pd

Keywords: parkinson's disease
characterization of baseline biomarker variability in participants with hepatocellular carcinoma (mk-0000-215)

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to characterize the baseline variability of a panel of tissue (tumor and adjacent) and blood-based biomarkers obtained from participants with hepatocellular carcinoma (hcc). the primary hypothesis is that the upper bound of the 80% confidence interval of log beta-catenin protein or messenger rna (mrna) expression from one core needle biopsy (cnb) equivalent is =\< 0.65.


Eligibility criteria:
inclusion criteria: * diagnosed with hcc. * candidate for surgical resection or has no contraindications to mri procedures. exclusion criteria: * prior loco-regional treatment of tumor, unless there is untreated tumor present representing a distinct untreated nodule. * confirmed or suspected diagnosis of fibrolamellar hcc, mixed hcc/cholangiocarcinoma or metastatic tumor. * had a liver transplant.

Keywords: hepatocellular carcinoma mri pharmacogenomics beta-catenin
efficacy and safety of a new chewable versus the swallowable tablet of mebendazole against hookworm

Conditions: Hookworm Infections

Summary: the rational of this study is to provide evidence on the safety and efficacy of a new chewable tablet of mebendazole compared to the standard tablet in preschool- and school-aged children infected with hookworm.


Eligibility criteria:
inclusion criteria: * male or female children aged between 3 and 12 years; * written informed consent signed by caregiver; * was examined by a study physician before treatment; * provided two stool samples at baseline; * hookworm epg \> 100 and at least two kato-katz thick smears slides with more than one hookworm egg; exclusion criteria: * pregnant; * presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, such as can upon initial clinical assessment; * suffers from severe anemia (hb \< 80 g/l); * received anthelminthic treatment or metronidazole within past four weeks. * attending other clinical trials during the study.

Keywords: mebendazole chewable tablet hookworm soil-transmitted helminths efficacy safety acceptability
vitamin a supplementation at birth and atopy in childhood

Conditions: Atopy; Asthma; Eczema; Food Allergy

Summary: introduction eight trials studying the effect of providing neonatal vitamin a supplementation (nvas) have been reported, and another four are underway to test whether nvas should become who policy. three of the four african trials were conducted by the bandim health project (bhp) in guinea-bissau. one of them was a two-by-two factorial trial among low-birth-weight children. from 2004-2008, the children were randomly allocated to 25,000 iu vitamin a or placebo at birth, and furthermore to bcg vaccination at birth or later as is local policy. in 2011, the investigators conducted a follow-up study. a remarkably strong harmful effect of nvas on atopy and wheezing was found (manuscript under review). seen in the context that nvas may soon become a who policy it is obviously worrying if nvas is associated with a higher risk of atopy and wheezing. the investigators therefore aim to conduct a similar follow-up study of participants in the first nvas trial conducted in guinea-bissau from 2002-2004, among normal-birth-weight infants, to test whether nvas is associated with an increased risk of atopy and wheezing and other allergic symptoms as well as growth. methods study population: from 2002-2004 bhp conducted a randomised trial of nvas. the investigators recruited newborns when they came for bcg vaccination. provided parental consent, they received an oral supplement of 50,000 iu vitamin a or placebo. study design: this study will be a follow-up study of the cohort of children randomised to nvas (intervention) or placebo (current policy) together with bcg vaccine at birth. other exposures: the investigators will also investigate the effect of receiving an additional dose of measles vaccine and the timing of dtp vaccine on the development of atopy. assessment of outcomes: the investigators will visit all children at the last known address. height, weight and mid upper arm circumference will be measured. bcg scar will be examined and vaccination card details recorded by the field assistant. children will be excluded from skin prick testing (spt) if they have a history suggestive of anaphylaxis or are currently using anti-histamine medication. spt will be performed using aero-allergens, food allergens and positive histamine and negative saline control. the mother or guardian will be interviewed by a local assistant. symptoms of eczema and asthma as well as food allergy will be assessed. statistical analysis: effect of randomisation group and other factors on outcomes will be analysed in multivariable regression models. all analyses will be adjusted for skin prick tester. all analyses will be conducted stratified by sex.


Eligibility criteria:
inclusion criteria: * enrolled at birth in nct00168610 exclusion criteria: * children with history suggestive of anaphylaxis will be excluded from skin prick testing but included in the study population

Keywords: vitamin a supplementation bcg vaccination diphtheria-tetanus-pertussis vaccination measles vaccination atopy
msb11022 in moderate to severe chronic plaque psoriasis

Conditions: Psoriasis; Plaque Type Psoriasis; Moderate to Severe Plaque Psoriasis

Summary: the purpose of this study was to compare the efficacy, safety and immunogenicity of msb11022 and humira® in adult subjects with moderate to severe chronic plaque type psoriasis.


Eligibility criteria:
inclusion criteria: * male or female participants greater than or equal to (\>=) 18 years old with a clinical diagnosis of stable moderate to severe plaque psoriasis (defined by psoriasis area and severity index \[pasi\] score \>=12, physician global assessment \[pga\] score \>=3, and \>=10% of body surface area affected at screening and baseline \[day 1 of week 1\]) who have a history of receipt of or are candidates for systemic therapy or phototherapy for active plaque-type psoriasis despite topical therapy * participants must not have received more than 1 biologic therapy * other protocol-defined inclusion criteria could apply exclusion criteria: * participants was excluded if they have erythrodermic, pustular, guttate, or medication-induced forms of psoriasis or other active skin diseases/infections that may interfere with the evaluation of plaque psoriasis * participants must not have received adalimumab or an investigational or licensed biosimilar of adalimumab; topical therapies for the treatment of psoriasis or ultraviolet b phototherapy within 2 weeks of investigational medicinal product (imp) administration or plan to take such treatment during the trial; or psoralen combined with ultraviolet a phototherapy or nonbiological systemic therapies for psoriasis within 4 weeks prior to imp administration * participants was excluded if they have a history of an ongoing, chronic, or recurrent infectious disease (except for latent tuberculosis \[tb\]); history of active tb; or a history of hypersensitivity to any component of the imp formulation, comparable drugs, or latex * other protocol-defined exclusion criteria could apply

Keywords: adalimumab msb11022 psoriasis phase iii
continuous positive airway pressure for acute pulmonary edema

Conditions: Pulmonary Edema; Dyspnea; Paroxysmal; Congestive Heart Failure

Summary: the investigators hypothesise that cpap + pharmaceutical treatment, compared to pharmaceutical treatment alone, improves the respiratory and hemodynamic status of the patients before h2 after the inclusion time and decreases the rate of death and tracheal intubation during the first 48 hours.

patients are included at home after informed consent by the emergency medical team and transported during the following 2 hours to a cardiac intensive care unit were the treatment is purchased as well. randomization process has been done previously with envelopes ; group a : pharmaceutical treatment alone , b pharmaceutical plus cpap. medical treatment includes furosemide and nitroglycerin (continuous perfusion and bolus), inotropes if needed, and all other specific treatment required (ex : anti antiarrhythmic drugs). doses are free, adapted to the clinical response for respiratory and hemodynamic distress. cpap is a passive high flow venturi system device alimented by a hyperbaric oxygen. fio2 can be controlled and adapted to the pulsed oxygen saturation. pep must be initially celled at least at 7.5 cmh2o and increased to 10 if well tolerated.

Eligibility criteria:
inclusion criteria: * age \> 18 * acute respiratory insufficiency with hypoxia in air * killip score from 2 to 4 * absence of known st elevation acute coronary syndrome * accepted inform consent. exclusion criteria: * age \< 18 * immediate intubation criteria (bradypnea, coma status) * refractory shock

Keywords: continuous positive airway pressure outcome measure clinical trial
treating bacterial overgrowth in parkinson's disease

Conditions: Parkinson's Disease; Small Intestinal Bacterial Overgrowth

Summary: this study investigates the effect of treating small intestinal bacterial overgrowth (sibo) in patients with parkinson's disease (pd). it will test the hypothesis that treating sibo with the antibiotic rifaximin will improve motor complications in previously sibo-positive pd patients.

parkinson's disease (pd) patients with motor fluctuations will be screened for the presence of small intestinal bacterial overgrowth (sibo) using two hydrogen breath tests. sibo-positive individuals will be eligible to enroll, and randomized to receive either rifaximin or placebo. this study includes two treatment regimens (including a placebo control), designed so that all patients will receive the active drug at some point during the trial. motor outcomes will be followed for 3 or 6 months following enrollment, depending on the treatment arm to which the subject has been assigned. the primary endpoint is to assess the effect of rifaximin treatment to decrease "off" time in sibo-positive pd patients. this pilot study will support the design of a larger, randomized controlled trial investigating the effect of sibo eradication on reducing motor complications in pd patients with motor fluctuations. the current proposal is designed to demonstrate our ability to detect and treat sibo in pd patients with motor fluctuations, to inform selection of the best sibo detection method, to determine the optimal timeline for assessing motor endpoints, and to estimate the duration of benefits after treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd * daily "off" time ≥ 4 hours * no changes in levodopa or any other dopaminergic medications expected during the course of the study * will be screened for cognitive ability (montreal cognitive assessment score of ≥ 24) prior to enrollment * will be screened for presence of sibo prior to enrollment exclusion criteria: * any comorbid non-pd-associated gastrointestinal (e.g., achlorhydria) or systemic diseases that may alter absorption or confound the study results * exposure to proton pump inhibitors, immunosuppressive drugs, medications that affect gi motility (such as prokinetics, anticholinergics, and tricyclic antidepressants), antibiotics or any other drugs that affect the intestinal flora (such as laxatives) within a month prior to enrollment. * prior deep brain stimulation or ablative functional neurosurgery. * prior allergy to rifaximin * women who are pregnant, lactating, or plan to become pregnant.
aflibercept in patients with pigment epithelial detachments (ped)

Conditions: Pigment Epithelial Detachment

Summary: uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment secondary to amd


Eligibility criteria:
inclusion criteria: * patients with vascular ped due to amd * male or female patients with the age \> 50 years * angiographic and via oct ensured ped ≥ 200 µm in the eye for treatment * written informed consent * best corrected visual acuity (etdrs-visus): 24 - 73 letters within exclusion criteria: * patients that do not fulfill the a. m. inclusion criteria * patients which have been treated with steroids or with verteporfin via photodynamic therapy or focal lasercoagulation treatment until 3 months before, * anti vegf therapy until 1 month before screening * patients with other retinal vascular diseases including diabetic rethinopathia or retinal vein occlusion * other ocular operative procedurs 3 months before screening * anamnesis of non controlled glaucoma * active or intraocular inflammation or inflammation of ocular adnexa * subfoveal fibrosis within study eye * larger surgical interventions 1 month before screening * anamnesis of serious cardiovascular diseases or stroke 6 months before srceening * allergy of components of the study medication * patients which might be not compliant * patients participating at another clinical trial at the same time * pregnancy, breastfeeding, women in child-bearing years without using a safe contraception method * chronical alcohol- or drug abuse within the last year * lack of capacity and/or knowledge of german language * neurologic disease i. e. multiple sclerosis
efficacy of ventavis used in real-life setting.

Conditions: Pulmonary Arterial Hypertension

Summary: this is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with ventavis. typical clinical measures and quality of life will be prospectively followed in 12 months period.


Eligibility criteria:
inclusion criteria: * pulmonary arterial hypertension in who functional class iii or iv * age 18+ * patients newly treated with ventavis or switched from sildenafil exclusion criteria: * retrospective documentation is not allowed

Keywords: pulmonary arterial hypertension inhaled iloprost quality of life
telemedicine with metabolic syndrome

Conditions: Metabolic Syndrome; Life Style

Summary: investigation of the effect of a 3-month telemedicine-led lifestyle intervention on cardiovascular risk factors, functional indicators, in patients with metabolic syndrome.

the patients are using mobile phone-based nutrition diary with heart rate monitoring watch (including activity meter) connected to a mobile phone with bluetooth technology worn on a wrist. these devices, and the weight scale, blood pressure monitor are connected with bluetooth to an it system, that transmits and displays data from these devices. the patients are using the devices during 3 months, and get instructions about lifestyle.

Eligibility criteria:
inclusion criteria: * age between 18 years and 75 years * presence of at least three of the following five risk factors (metabolic syndrome atp iii criteria): 1. waist width above 102 cm in men and 88 cm in women 2. treated diabetes or blood sugar above 5.6 mmol / l 3. treated hypertension or spontaneous blood pressure ≥ 130/85 mmhg 4. fibrate treatment or triglyceride levels above 1.7 mmol / l 5. blood hdl cholesterol levels below 1.03 mmol / l in men and 1.3 mmol / l in women exclusion criteria: * low level of physical activity (less than 30 minutes a day) * it proficiency at least for basic use of mobile phones (answering / making voice calls). * for women with childbearing potential, by definition, all women who are able to conceive physiologically use dual contraception * signing an informed consent. * the subject communicates well with the investigator and is able to help understand and adhere to the requirements of the study plan.

Keywords: telemedicine